Book Description
This book comprehensively examines the landscape of immunotherapeutic modalities in cancer treatment, with a specific focus on Chimeric Antigen Receptor (CAR) T-cell therapy, immune checkpoint inhibitors, and other innovative approaches. The CAR T-cell therapy represents a groundbreaking approach wherein T-cells are genetically engineered to recognize and eradicate tumor cells expressing specific antigens. The book briefly discussed the clinical applications and challenges associated with CAR T-cell therapy, case studies highlighting its remarkable efficacy in malignancies, and emerging potential in solid tumors. Additionally, immune checkpoint inhibitors have transformed the treatment of various cancers by disrupting inhibitory signalling pathways and reinvigorating antitumor immune responses. This book explores the mechanisms, clinical efficacy, and challenges of immune checkpoint blockade, including strategies to overcome resistance and improve patient outcomes. Furthermore, it promises other innovative immunotherapeutic strategies, such as tumor vaccines, cytokine therapies, and adoptive cell transfer. Personalized Approaches emphasize their potential synergies and future directions in combination with existing modalities. Overall, this book provides insights into the evolving landscape of cancer immunotherapy, emphasizing the significant strides made in improving patient outcomes and the ongoing efforts to optimize treatment efficacy and durability while minimizing adverse effects.